
    
      This is a Phase 2, double-blind, double-dummy, placebo-controlled, randomized, parallel
      group, multicentre study.

      Subjects with a diagnosis of moderate to severe dyskinesia in Parkinson's disease (PD) will
      complete a Screening Visit to assess eligibility to participate in the study.

      Subjects will continue with their usual levodopa treatment regimen for the duration of study
      participation.

      The screening assessment period will be a minimum of 1 week up to a maximum of 6 weeks.
      Subjects deemed to be eligible at the end of the Screening Visit will be randomly assigned in
      a 1:1:1 ratio to receive either 1 of the 2 dose combinations of JM-010 and 1 placebo, or 2
      placebos as per the double-dummy study design. The randomized subjects will be followed
      treatment periods for 12 weeks and safety follow periods for 2 weeks, including
      pharmacokinetic (PK) sub-study.
    
  